Reliability and Validity of the Turkish Version of General Sleep Disturbance Scale (GSDS-T) in Multiple Sclerosis

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The GSDS-T was developed by Lee KA to assess difficulty falling asleep, waking up during sleep, sleep quality, and daytime alertnes. The Turkish validity and reliability of the scale have been conducted on stroke patients but not on multiple sclerosis patients. The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Individuals over the age of 18 who have been diagnosed with Multiple Sclerosis for at least two years,

• Those with an EDSS score \>2.

• Those without symptoms of insomnia according to the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria

• Individuals whose native language is Turkish and who have the ability to speak and understand.

Locations
Other Locations
Turkey
Bağcılar Training and Research Hospital
RECRUITING
Bağcılar
Contact Information
Primary
EMEL METE
meteemel53@gmail.com
+905376096265
Time Frame
Start Date: 2025-04-15
Estimated Completion Date: 2025-08-10
Participants
Target number of participants: 126
Treatments
Patients with MS
Turkish Validity and Reliability of The GSDS-T in patients with multiple sclerosis The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis. It has 21 questions. This study will be conducted on patients with multiple sclerosis. In order to evaluate the validity of the GSDS-T, the Pittsburgh Sleep Quality Index (PSQI) which can evaluate sleep quality and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.
Related Therapeutic Areas
Sponsors
Leads: Istanbul Medeniyet University

This content was sourced from clinicaltrials.gov